Primary Effusion Lymphoma: Is Dose-Adjusted-EPOCH Worthwhile Therapy?

Kegan Jessamy, Fidelis O. Ojevwe, Ravi Doobay, Rana Naous, John Yu, Sheila M. Lemke

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Fingerprint

Dive into the research topics of 'Primary Effusion Lymphoma: Is Dose-Adjusted-EPOCH Worthwhile Therapy?'. Together they form a unique fingerprint.

Medicine & Life Sciences